JP2008542209A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008542209A5 JP2008542209A5 JP2008512656A JP2008512656A JP2008542209A5 JP 2008542209 A5 JP2008542209 A5 JP 2008542209A5 JP 2008512656 A JP2008512656 A JP 2008512656A JP 2008512656 A JP2008512656 A JP 2008512656A JP 2008542209 A5 JP2008542209 A5 JP 2008542209A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- benzoic acid
- subject
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 10
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical group S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 8
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 8
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 8
- 229960004963 mesalazine Drugs 0.000 claims description 8
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 7
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 104
- 230000004968 inflammatory condition Effects 0.000 claims 14
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 208000029742 colonic neoplasm Diseases 0.000 claims 8
- 239000005711 Benzoic acid Substances 0.000 claims 6
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims 5
- 208000011231 Crohn disease Diseases 0.000 claims 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- -1 2-acetylamino-3-mercapto-propionyloxy Chemical group 0.000 claims 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000008064 anhydrides Chemical class 0.000 claims 3
- DBDMFRBFYLANQK-UHFFFAOYSA-N [4-(5-sulfanylidenedithiol-3-yl)phenyl] 5-amino-2-hydroxybenzoate Chemical compound NC1=CC=C(O)C(C(=O)OC=2C=CC(=CC=2)C=2SSC(=S)C=2)=C1 DBDMFRBFYLANQK-UHFFFAOYSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- CINBWUSRSNZBFY-UHFFFAOYSA-N 2,5-diamino-5-sulfanylidenepentanoic acid Chemical compound OC(=O)C(N)CCC(N)=S CINBWUSRSNZBFY-UHFFFAOYSA-N 0.000 claims 1
- KAANEFXFUHDVPN-UHFFFAOYSA-N 2-[[2-(5-amino-2-hydroxybenzoyl)oxyacetyl]amino]-3-sulfanylpropanoic acid Chemical compound NC1=CC=C(O)C(C(=O)OCC(=O)NC(CS)C(O)=O)=C1 KAANEFXFUHDVPN-UHFFFAOYSA-N 0.000 claims 1
- TXYRSZFMJWFHND-UHFFFAOYSA-N 2-sulfanylethyl hydrogen sulfate Chemical compound OS(=O)(=O)OCCS TXYRSZFMJWFHND-UHFFFAOYSA-N 0.000 claims 1
- MFEKCQPTGSAYKB-UHFFFAOYSA-N 3-[(2-amino-2-sulfanylideneethoxy)carbonylamino]benzoic acid Chemical compound NC(=S)COC(=O)NC1=CC=CC(C(O)=O)=C1 MFEKCQPTGSAYKB-UHFFFAOYSA-N 0.000 claims 1
- QFBHGYAVQZQYMO-UHFFFAOYSA-N 3-[(4-carbamothioylphenoxy)carbonylamino]benzoic acid Chemical compound C1=CC(C(=S)N)=CC=C1OC(=O)NC1=CC=CC(C(O)=O)=C1 QFBHGYAVQZQYMO-UHFFFAOYSA-N 0.000 claims 1
- KEFUFRLCEPVDHV-UHFFFAOYSA-N 3-[(5-amino-1-hydroxy-5-sulfanylidenepentan-2-yl)carbamoylamino]benzoic acid Chemical compound NC(=S)CCC(CO)NC(=O)NC1=CC=CC(C(O)=O)=C1 KEFUFRLCEPVDHV-UHFFFAOYSA-N 0.000 claims 1
- QEIIGNLGMJELAK-UHFFFAOYSA-N 3-[[4-(5-sulfanylidenedithiol-3-yl)phenyl]diazenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(N=NC=2C=CC(=CC=2)C=2SSC(=S)C=2)=C1 QEIIGNLGMJELAK-UHFFFAOYSA-N 0.000 claims 1
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 claims 1
- BLINMQRVKJYUFX-UHFFFAOYSA-N 5-[(1-carboxy-2-sulfanylethyl)carbamoyl-methoxycarbonylamino]-2-hydroxybenzoic acid Chemical compound SCC(C(O)=O)NC(=O)N(C(=O)OC)C1=CC=C(O)C(C(O)=O)=C1 BLINMQRVKJYUFX-UHFFFAOYSA-N 0.000 claims 1
- CBFMEZVPXSOKET-UHFFFAOYSA-N 5-[(2,5-diamino-5-sulfanylidenepentanoyl)amino]-2-hydroxybenzoic acid Chemical compound NC(=S)CCC(N)C(=O)NC1=CC=C(O)C(C(O)=O)=C1 CBFMEZVPXSOKET-UHFFFAOYSA-N 0.000 claims 1
- DLINENPDJAWTRW-UHFFFAOYSA-N 5-[(2-acetamido-3-sulfanylpropanoyl)amino]-2-hydroxybenzoic acid Chemical compound CC(=O)NC(CS)C(=O)NC1=CC=C(O)C(C(O)=O)=C1 DLINENPDJAWTRW-UHFFFAOYSA-N 0.000 claims 1
- MZDXTCXUNOBCQO-UHFFFAOYSA-N 5-[(4-amino-1-carboxy-4-sulfanylidenebutyl)diazenyl]-2-hydroxybenzoic acid Chemical compound NC(=S)CCC(C(O)=O)N=NC1=CC=C(O)C(C(O)=O)=C1 MZDXTCXUNOBCQO-UHFFFAOYSA-N 0.000 claims 1
- CRTFCLLAVDRVOO-UHFFFAOYSA-N 5-[[2-[(1-carboxy-2-sulfanylethyl)amino]-2-oxoethyl]diazenyl]-2-hydroxybenzoic acid Chemical compound OC(=O)C(CS)NC(=O)CN=NC1=CC=C(O)C(C(O)=O)=C1 CRTFCLLAVDRVOO-UHFFFAOYSA-N 0.000 claims 1
- UMBFBJOWJCSNKO-UHFFFAOYSA-N 5-amino-2-(2,5-diamino-5-sulfanylidenepentanoyl)oxybenzoic acid Chemical compound NC(=S)CCC(N)C(=O)OC1=CC=C(N)C=C1C(O)=O UMBFBJOWJCSNKO-UHFFFAOYSA-N 0.000 claims 1
- FQGCHJYMDJOHAT-UHFFFAOYSA-N 5-amino-2-(2-amino-2-sulfanylideneethoxy)carbonyloxybenzoic acid Chemical compound NC(=S)COC(=O)OC1=CC=C(N)C=C1C(O)=O FQGCHJYMDJOHAT-UHFFFAOYSA-N 0.000 claims 1
- DOBTUCQCZRTKRD-UHFFFAOYSA-N 5-amino-2-(2-sulfanylethoxysulfonyloxy)benzoic acid Chemical compound NC1=CC=C(OS(=O)(=O)OCCS)C(C(O)=O)=C1 DOBTUCQCZRTKRD-UHFFFAOYSA-N 0.000 claims 1
- YKOVUZBGGQFJOI-UHFFFAOYSA-N 5-amino-2-(4-carbamothioylphenoxy)carbonyloxybenzoic acid Chemical compound C1=CC(C(=S)N)=CC=C1OC(=O)OC1=CC=C(N)C=C1C(O)=O YKOVUZBGGQFJOI-UHFFFAOYSA-N 0.000 claims 1
- HPKZJKJXIKHGRM-UHFFFAOYSA-N 5-amino-2-[(4-amino-1-carboxy-4-sulfanylidenebutyl)carbamoyloxy]benzoic acid Chemical compound NC(=S)CCC(C(O)=O)NC(=O)OC1=CC=C(N)C=C1C(O)=O HPKZJKJXIKHGRM-UHFFFAOYSA-N 0.000 claims 1
- GNYKDUWXFOYQJM-UHFFFAOYSA-N 5-amino-2-[2-[(1-carboxy-2-sulfanylethyl)amino]-2-oxoethoxy]carbonyloxybenzoic acid Chemical compound NC1=CC=C(OC(=O)OCC(=O)NC(CS)C(O)=O)C(C(O)=O)=C1 GNYKDUWXFOYQJM-UHFFFAOYSA-N 0.000 claims 1
- OFFGCRIILKXXJW-UHFFFAOYSA-N 5-amino-2-[4-(5-sulfanylidenedithiol-3-yl)phenoxy]carbonyloxybenzoic acid Chemical compound OC(=O)C1=CC(N)=CC=C1OC(=O)OC1=CC=C(C=2SSC(=S)C=2)C=C1 OFFGCRIILKXXJW-UHFFFAOYSA-N 0.000 claims 1
- 206010017969 Gastrointestinal inflammatory conditions Diseases 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- OKNZGKUVCKVSKJ-UHFFFAOYSA-N S=C1C=C(SS1)C1=CC=C(OC(=O)NC2=C(C(=O)O)C=CC=C2)C=C1 Chemical compound S=C1C=C(SS1)C1=CC=C(OC(=O)NC2=C(C(=O)O)C=CC=C2)C=C1 OKNZGKUVCKVSKJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-M mesalaminate(1-) Chemical compound NC1=CC=C(O)C(C([O-])=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-M 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 2
- 102000016924 KATP Channels Human genes 0.000 description 2
- 108010053914 KATP Channels Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-M hydrosulfide Chemical compound [SH-] RWSOTUBLDIXVET-UHFFFAOYSA-M 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- 0 *CCCC(N)=S Chemical compound *CCCC(N)=S 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- DWKPPFQULDPWHX-UHFFFAOYSA-N CC(C(OC)=O)N Chemical compound CC(C(OC)=O)N DWKPPFQULDPWHX-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 208000002389 Pouchitis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000010282 redox signaling Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 230000019086 sulfide ion homeostasis Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2005/000819 WO2006125293A1 (en) | 2005-05-27 | 2005-05-27 | Derivatives of 4- or 5-aminosalicylic acid |
| CAPCT/CA2005/000819 | 2005-05-27 | ||
| PCT/CA2006/000484 WO2006125295A1 (en) | 2005-05-27 | 2006-03-31 | Derivatives of 4-or 5-aminosalicylic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008542209A JP2008542209A (ja) | 2008-11-27 |
| JP2008542209A5 true JP2008542209A5 (https=) | 2009-06-18 |
| JP5221341B2 JP5221341B2 (ja) | 2013-06-26 |
Family
ID=37451592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512656A Expired - Fee Related JP5221341B2 (ja) | 2005-05-27 | 2006-03-31 | ４−または５−アミノサリチル酸誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7910568B2 (https=) |
| EP (1) | EP1883645B1 (https=) |
| JP (1) | JP5221341B2 (https=) |
| KR (1) | KR101298880B1 (https=) |
| CN (1) | CN101238137B (https=) |
| AT (1) | ATE514704T1 (https=) |
| AU (1) | AU2006251803B2 (https=) |
| BR (3) | BR122019014196B8 (https=) |
| CA (1) | CA2609224C (https=) |
| ES (1) | ES2368650T3 (https=) |
| IL (1) | IL187319A (https=) |
| NO (1) | NO340528B1 (https=) |
| NZ (1) | NZ563354A (https=) |
| RU (1) | RU2414476C2 (https=) |
| UA (1) | UA96264C2 (https=) |
| WO (2) | WO2006125293A1 (https=) |
| ZA (1) | ZA200710472B (https=) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7741359B2 (en) | 2005-05-27 | 2010-06-22 | Antibe Therapeutics Inc. | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
| DK2057139T3 (da) | 2006-07-18 | 2013-11-18 | Antibe Holdings Inc | Hydrogensulfidderivater af non-steroide anti-inflammatoriske lægemidler |
| UA102216C2 (ru) * | 2006-07-18 | 2013-06-25 | Антиб Терапьютикс Инк. | 4-гидрокситиобензамидные производной лекарственных веществ |
| CN101680086B (zh) * | 2007-05-21 | 2012-05-23 | 乔治洛德方法研究和开发液化空气有限公司 | 用于半导体领域的新型金属前体 |
| CN101541780B (zh) * | 2007-06-08 | 2012-12-05 | 成都地奥九泓制药厂 | 贝特羧酸酯类化合物及其制备方法和用途 |
| EP2062578A1 (en) * | 2007-11-12 | 2009-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Novel use of chemical compounds for the treatment of AIDS |
| ITMI20072429A1 (it) * | 2007-12-24 | 2009-06-25 | Giuliani Int Ltd | Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca |
| US8569466B2 (en) | 2008-09-10 | 2013-10-29 | Nnochiri Ekwuribe | Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers |
| EP2744487B1 (en) | 2011-08-15 | 2016-10-05 | Research Foundation Of The City University Of New York | No- and h2s- releasing compounds |
| US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| WO2013168021A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| WO2013167985A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
| US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| EP2852569B1 (en) | 2012-05-23 | 2020-10-14 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| AU2013264820A1 (en) | 2012-05-23 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of mucositis |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| CN102807557B (zh) * | 2012-08-21 | 2015-02-04 | 苏州大学 | 3h-1,2-二硫环戊烯-3-硫酮类化合物及其应用 |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| CN104364231A (zh) | 2012-09-08 | 2015-02-18 | 塞利克斯比奥私人有限公司 | 用于治疗炎症和脂质异常的组合物和方法 |
| CA2905435A1 (en) * | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| CN103254257A (zh) * | 2013-04-18 | 2013-08-21 | 山西医科大学 | 一种4-氨基水杨酸糖苷类衍生物及其制备方法 |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| EP3004049B1 (en) | 2013-06-04 | 2018-09-05 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| CN103483214B (zh) * | 2013-06-09 | 2015-04-29 | 西安交通大学 | 一种化合物及其制备方法和抗溃疡性结肠炎用途 |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| EP3240779B1 (en) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| JP6698643B2 (ja) | 2014-09-29 | 2020-05-27 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 多発性硬化症の治療のための組成物及び方法 |
| AU2014414316B2 (en) | 2014-10-27 | 2020-04-09 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| CA2973178C (en) | 2015-01-06 | 2022-11-01 | Cellix Bio Private Limited | Bupivacaine derivatives and their use in the treatment of inflammation and pain |
| CN109640965A (zh) | 2016-08-11 | 2019-04-16 | 塞尔利克斯生物私人有限公司 | 用于治疗肠易激综合征的组合物和方法 |
| WO2019008441A1 (en) * | 2017-07-04 | 2019-01-10 | Intocell, Inc. | COMPOUNDS COMPRISING A CLIABABLE BIT AND USES THEREOF |
| US10100005B1 (en) * | 2017-11-17 | 2018-10-16 | Eclipse Therapeutics, LLC | Mesalazine derivatives |
| KR20220055697A (ko) | 2020-10-27 | 2022-05-04 | 강원대학교산학협력단 | 살리신을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| CN113398112A (zh) * | 2021-06-17 | 2021-09-17 | 西南医科大学 | FA介导的BBA/CM-β-CD靶向递药系统、制备方法及其应用 |
| CN115960075B (zh) * | 2021-10-08 | 2024-11-08 | 深圳枫语生物医药科技有限公司 | 一种咖啡酸衍生物及其制备方法和应用 |
| CN114605277B (zh) * | 2022-04-18 | 2022-10-11 | 宁波怡和医药科技有限公司 | 一种美沙拉嗪的合成方法 |
| CN116444408B (zh) * | 2023-06-14 | 2023-09-26 | 山东大学 | 一种多靶点型双硫仑衍生物、药物组合物及其抗肿瘤应用 |
| CN117679402A (zh) * | 2024-01-10 | 2024-03-12 | 北京化工大学 | 莱菔素在制备治疗溃疡性结肠炎药物中的应用 |
| WO2025248450A1 (en) * | 2024-05-28 | 2025-12-04 | Antibe Therapeutics, Inc. | H2s-releasing mesalamine analogs |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE900937C (de) * | 1952-05-14 | 1954-01-04 | Dr Bruno Boettcher | Verfahren zur Herstellung schwefelhaltiger organischer Verbindungen |
| BE642496A (https=) | 1963-01-16 | 1964-07-01 | ||
| US4161550A (en) * | 1977-09-21 | 1979-07-17 | The Procter & Gamble Company | Meat aroma precursor composition |
| JPS57500432A (https=) | 1980-03-20 | 1982-03-11 | ||
| US4412992A (en) * | 1980-07-21 | 1983-11-01 | Biorex Laboratories Limited | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith |
| US4440763A (en) * | 1981-03-18 | 1984-04-03 | Block Drug Company, Inc. | Use of 4-aminosalicyclic acid as an anti-inflammatory agent |
| JPH04154773A (ja) * | 1990-10-15 | 1992-05-27 | Green Cross Corp:The | チアゾール誘導体 |
| US20050090553A1 (en) * | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| CA2204747C (en) * | 1995-09-08 | 2009-05-05 | Elena Carceller | New azo derivatives of 5-aminosalicylic acid |
| SE9700934D0 (sv) * | 1997-03-14 | 1997-03-14 | Astra Ab | New formulation |
| IT1311923B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| US6602915B2 (en) | 2000-07-27 | 2003-08-05 | Rutgers, The State University Of New Jersey | Therapeutic azo-compounds for drug delivery |
| AU2001285489A1 (en) * | 2000-08-29 | 2002-03-13 | Nobex Corporation | 5-ASA derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith |
| WO2005072113A2 (en) | 2004-01-20 | 2005-08-11 | Harty Richard F | Compositions and methods of treatment for inflammatory diseases |
| EP1645288A1 (en) | 2004-10-07 | 2006-04-12 | CTG Pharma S.r.l. | New nuclear transcription factors regulators |
| EP1836160A1 (en) | 2004-12-24 | 2007-09-26 | CTG Pharma S.r.l. | Compounds for treating metabolic syndrome |
| US7498355B2 (en) * | 2005-05-27 | 2009-03-03 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
-
2005
- 2005-05-27 WO PCT/CA2005/000819 patent/WO2006125293A1/en not_active Ceased
-
2006
- 2006-03-31 BR BR122019014196A patent/BR122019014196B8/pt active IP Right Grant
- 2006-03-31 UA UAA200714842A patent/UA96264C2/ru unknown
- 2006-03-31 KR KR1020077030493A patent/KR101298880B1/ko not_active Expired - Fee Related
- 2006-03-31 EP EP06721742A patent/EP1883645B1/en not_active Expired - Lifetime
- 2006-03-31 BR BR122019014203A patent/BR122019014203B8/pt active IP Right Grant
- 2006-03-31 RU RU2007148924/04A patent/RU2414476C2/ru active
- 2006-03-31 CA CA2609224A patent/CA2609224C/en not_active Expired - Lifetime
- 2006-03-31 AT AT06721742T patent/ATE514704T1/de not_active IP Right Cessation
- 2006-03-31 NZ NZ563354A patent/NZ563354A/en not_active IP Right Cessation
- 2006-03-31 JP JP2008512656A patent/JP5221341B2/ja not_active Expired - Fee Related
- 2006-03-31 ES ES06721742T patent/ES2368650T3/es not_active Expired - Lifetime
- 2006-03-31 CN CN2006800251569A patent/CN101238137B/zh not_active Expired - Fee Related
- 2006-03-31 AU AU2006251803A patent/AU2006251803B2/en not_active Ceased
- 2006-03-31 BR BRPI0605840-0A patent/BRPI0605840A/pt not_active Application Discontinuation
- 2006-03-31 ZA ZA200710472A patent/ZA200710472B/xx unknown
- 2006-03-31 US US11/915,305 patent/US7910568B2/en not_active Expired - Fee Related
- 2006-03-31 WO PCT/CA2006/000484 patent/WO2006125295A1/en not_active Ceased
-
2007
- 2007-11-12 IL IL187319A patent/IL187319A/en active IP Right Grant
- 2007-12-21 NO NO20076625A patent/NO340528B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008542209A5 (https=) | ||
| JP5221341B2 (ja) | ４−または５−アミノサリチル酸誘導体 | |
| Bhandari et al. | Design, synthesis and evaluation of antiinflammatory, analgesic and ulcerogenicity studies of novel S-substituted phenacyl-1, 3, 4-oxadiazole-2-thiol and Schiff bases of diclofenac acid as nonulcerogenic derivatives | |
| AU593606B2 (en) | Novel phenolic thioethers and sulphoxides as inhibitors of 5-lipoxygenase | |
| US8541398B2 (en) | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs | |
| ES2922425T3 (es) | Profármacos de NSAIA con velocidades de penetración en piel y membranas muy elevadas y sus nuevos usos medicinales | |
| JP5408719B2 (ja) | 非ステロイド系抗炎症薬の硫化水素誘導体 | |
| JP4451595B2 (ja) | 炎症ベースの疾患用薬剤としてのニトロ誘導体 | |
| JP2009543813A5 (https=) | ||
| CA2660814C (en) | Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate | |
| JP2009543811A5 (https=) | ||
| WO2016159577A2 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
| WO2004046094A9 (en) | Histone deacetylase inhibitors | |
| US20070060544A1 (en) | 4-Nitro-2-[(4'-methoxy)-phenoxy]-methanesulfonanilide derivatives and their pharmaceutical use | |
| WO2008017903A1 (en) | Positively charged water-soluble prodrugs of aryl- and heteroarylacetic acids with very fast skin penetration rate | |
| Mahdi et al. | Synthesis, characterization and preliminary pharmacological evaluation of new non-steroidal anti-inflammatory pyrazoline derivatives | |
| US20090036516A1 (en) | Compounds for treating metabolic syndrome | |
| Yadav et al. | Synthesis of new chemical entities from paracetamol and NSAIDs with improved pharmacodynamic profile | |
| US20090275539A1 (en) | Nuclear Transcription Factors Regulators | |
| US20070197479A1 (en) | Derivatives of 4- or 5-aminosalicylic acid | |
| US20080207751A1 (en) | Sulindac Derivatives for Treatment of Cancer | |
| TW200407144A (en) | Hydroxamate derivatives of non-steroidal anti-inflammatory drugs | |
| CA3112073A1 (en) | Aromatic compounds and pharmaceutical uses thereof | |
| Halen et al. | Synthesis and Pharmacological Evaluation of Some Dual‐Acting Amino‐alcohol Ester Derivatives of Flurbiprofen and 2‐[1, 1′‐Biphenyl‐4‐yl] acetic Acid: A Potential Approach to Reduce Local Gastrointestinal Toxicity | |
| CN112574172B (zh) | 一种没食子酸硫化氢衍生物及其制备方法及医药用途 |